BLASUBCUTANEOUSSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ADMELOG SOLOSTAR (insulin lispro) by Sanofi is analogs, including insulin lispro products. Approved for type 2 diabetes mellitus, type 1 diabetes mellitus. First approved in 2017.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADMELOG SOLOSTAR is a rapid-acting insulin lispro analog delivered via prefilled pen for subcutaneous injection, indicated for glycemic control in adults with diabetes. It works by stimulating peripheral glucose uptake in muscle and fat while inhibiting hepatic glucose production, lipolysis, and proteolysis. This is a biosimilar formulation of the reference insulin lispro product.
$0.004BPart D
PeakADMELOG SOLOSTAR is in peak sales phase with modest Part D spending ($4M) and approximately 25K annual claims, indicating a niche position within the large insulin market with stable but limited commercial upside.
Mechanism of Action
analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
Pharmacologic Class:
Insulin Analog
Indications (2)
Worked on ADMELOG SOLOSTAR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.